The publication of SUMAVEL DosePro (sumatriptan injection) Needle-free Delivery system Phase 4 clinical study results were announced by Zogenix, Inc., a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. SAMUVEL was found to be an important treatment option for those with rapid-onset migraine attacks.
Headache, The Journal of Head and Face Pain is the official publication of the American Headache Society (AHS). In the journal, authors reported that patients who currently use triptan in the treatment of multiple migraine attacks reported a higher level of satisfaction, confidence and preference for SUMAVEL DosePro.
The publication, “Satisfaction With and Confidence in Needle-Free Subcutaneous Sumatriptan in Patients Currently Treated with Triptans,” is currently available online on the journal’s website.
Roger K. Cady, MD, associate executive chairman of the National Headache Foundation board of directors, founder of the Headache Care Center in Springfield, MO, and leading author of the study, said:
“The Phase 4 study results support the use of SUMAVEL DosePro as an important treatment option for migraine patients, such as those with aggressive, rapid-onset attacks. It provides a fast-acting and easy-to-use injectable triptan therapy option for patients to use as part of their migraine toolbox in conjunction with their oral triptan medications so that the right medication can be used for specific attacks.”
Additional commentary by Dr. Cady regarding migraine treatment and the SUMAVEL DosePro Phase 4 clinical data, which was highlighted during National Headache Month at the 2011 annual meeting of the AHS in Washington, D.C. is available online.
Adult patients diagnosed with migraine who are currently treated with triptans were evaluated by Zogenix in their Phase 4 open-label, multicenter study in the U.S. to assess patient’s response to SUMAVEL DosePro in terms of general satisfaction, confidence in the treatment, patient preference and treatment tolerability.
Over 200 patients who predominantly used oral triptan therapy for their migraine switched to SUMAVEL DosePro for a 60-day period, treating at least one and up to a maximum of four migraines and assessed their findings by using the Patient Perception of Migraine Questionnaire-Revised, or PPMQ-R, a validated instrument to evaluate patient satisfaction with migraine treatment through analysis of efficacy, functionality, ease of use and tolerability/side effects. The aim of the study was to assess overall satisfaction.
SUMAVEL DosePro (sumatriptan injection) is administered for acute treatment of migraine attacks, with or without aura, and acute treatment of cluster headache episodes.
SUMAVEL DosePro should only be used where a clear diagnosis of migraine or cluster headache has been diagnosed. SUMAVEL DosePro is not intended for the prophylactic therapy of migraine or in the management of hemiplegic or basilar migraine and should not be administered intravenously. In case a patient does not respond to the first dose of SUMAVEL DosePro after an attack, the diagnosis of migraine or cluster headache should be reconsidered before administrating a second dose.
Written by Petra Rattue